Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates

Journal of Virology

Volumn 75, Issue 9, 2001, Pages 4430-4434

  McGettigan, J P ^a   Foley, H D ^a   Belyakov, I M ^a   Berzofsky, J A ^a   Pomerantz, R J ^a   Schnell, M J ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; INOCULATION; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RABIES VIRUS; VIRUS ISOLATION; VIRUS RECOMBINANT;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENETIC VECTORS; HIV ENVELOPE PROTEIN GP160; HIV-1; HUMANS; MICE; MICE, INBRED BALB C; RABIES VIRUS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 0035043384     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.9.4430-4434.2001     Document Type: Article

References (38)

1. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques
2. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
3. Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees
4. Prime-boost immunization strategies against HIV
5. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
6. The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12
7. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus
8. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections
9. T lymphocyte responses in HIV-1 infection: Implications for vaccine development
10. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
11. Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development
12. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
13. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
14. Safety issues facing development of a live-attenuated, multiply deleted HIV-1 vaccine
15. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
16. Recombinant gp160 as a therapeutic vaccine for HIV-infection: Results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group
17. Anti-HIV cellular immunity: Recent advances towards vaccine design
18. Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain
19. + cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins
20. Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: Definition of minimum epitopes and analysis of the effects of sequence variation
21. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells
22. Importance of the nef gene for maintenance of high virus loads and for development of AIDS
23. Rabies virus superantigen
24. Evidence for a viral superantigen in humans
25. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions
26. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
27. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine
28. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model
29. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
30. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients
31. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids
32. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts
33. Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response
34. DNA vaccines for immunodeficiency viruses
35. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
36. Recombinant rabies virus as potential live-viral vaccines for HIV-1
37. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope
38. Genetic vaccines